LAVAL, QC / ACCESSWIRE / November 29, 2022 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (“Bausch Health” or the “Company”) has designated 1261229 B. C. Ltd., the particular entity that directly or indirectly holds 88. 7% of the issued and outstanding shares of Bausch + Lomb Corporation (“Bausch + Lomb”), as an unrestricted subsidiary from the Company in accordance with the terms of the Company’s debt documents. In connection therewith, all associated with the subsidiaries of 1261229 B. Chemical. Ltd., including Bausch + Lomb and its subsidiaries, are also now unhindered subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health financial debt documents.
The Company continues to evaluate potential options to maximize stakeholder value, which include its ongoing focus on its balance sheet and liquidity.
About Bausch Health
Bausch Health Businesses Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com plus connect with us on Twitter and LinkedIn .
This news release may contain forward-looking statements about the future performance of Bausch Health including the proposed plan to fully separate its vision health business, including the timing thereof, which may generally be identified by the use of the particular words “anticipates, ” “hopes, ” “expects, ” “intends, ” “plans, ” “should, ” “could, ” “would, ” “may, ” “believes, ” “subject to” and variations or even similar expressions. These statements are based upon the current expectations plus beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that will relate more broadly in order to Bausch Health’s overall company, including those more fully described inside Bausch Health’s most recent annual report on Form 10-K plus detailed through time to time in Bausch Health’s other filings with the U. S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
SOURCE: Bausch Health Companies Inc